GlassScriptPhysician profile
Jenny Pham
NPI 1639994619
$1,614.68
in general payments reported to CMS, 2019-2025
14 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $23.51 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $452.96 | 2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $232.93 | 2025 | Dupixent |
| Genzyme Corporation | $224.08 | 2025 | |
| Pfizer INC. | $124.98 | 2025 | |
| Novartis Pharmaceuticals Corporation | $108.79 | 2025 | |
| Glaxosmithkline, LLC. | $105.89 | 2025 | Nucala |
| Collegium Pharmaceutical, INC. | $88.29 | 2024-2025 | Xtampza |
| Takeda Pharmaceuticals U.S.A., INC. | $82.35 | 2025 | Eohilia, Cuvitru |
| Verona Pharma, INC. | $61.56 | 2025 | Ohtuvayre |
| Ars Pharmaceuticals Operations, INC. | $53.77 | 2025 | Neffy |
| Pharming Healthcare, INC. | $21.51 | 2025 | Ruconest |
| Leo Pharma INC. | $21.12 | 2025 | Anzupgo |
| Amgen INC. | $20.98 | 2025 | Tezspire |
| Galderma Laboratories, L.P. | $15.47 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.